



## Walter Stummer

### Contact

Walter Stummer

## Publications (4)

Neurooncology Working Group of the German Cancer Society, Simon M, Tonn J, Stummer W, Schaub C, Weller J, Kebir S, Schäfer N, Stuplich M, Vatter H, Misch M, Keil V, Nelles M, Glas M, Coch C, Pietsch T, Hattingen E, Schmid M, Fimmers R, Weller M, Wick W, Coenen M, Urbach H, Vajkoczy P, Galldiks N, Bullinger L, Goldbrunner R, Grauer O, Krex D, Kortmann R, Hau P, Sabel M, Schlegel U, Steinbach J, Mack F, Tzaridis T, Schnell O, Bähr O, Renovanz M, Weyerbrock A, Brehmer S, Suchorska B, Schmidt-Graf F, Ringel F, Kowalski T, Tabatabai G, Seidel C, Uhl M, Herrlinger U. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. *Lancet* 2019; 393:678–688.

Schäfer N, Proescholdt M, Steinbach J, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch M, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U. Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. *Neuro Oncol* 2018; 20:975–985.

Beier D, Proescholdt M, Reinert C, Pietsch T, Jones D, Pfister S, Hattingen E, Seidel C, Dirven L, Luerding R, Reijneveld J, Warmuth-Metz M, Bonsanto M, Bremer M, Combs S, Rieken S, Herrlinger U, Kuntze H, Mayer-Steinacker R, Moskopp D, Schneider T, Beringer A, Schlegel U, Stummer W, Welker H, Weyerbrock A, Paulsen F, Rutkowski S, Weller M, Wick W, Kortmann R, Bogdahn U, Hau P. Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). *Neuro Oncol* 2018; 20:400–410.

Herrlinger U, Kortmann R, Mehdorn M, Tüttenberg J, Mayer-Steinacker R, Fietkau R, Brehmer S, Mack F, Stuplich M, Kebir S, Kohnen R, Dunkl E, Leutgeb B, Proescholdt M, Pietsch T, Urbach H, Belka C, Stummer W, Gerlach R, Vajkoczy P, Schäfer N, Steinbach J, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch M, Uhl M, Maciaczyk J, Grau S, Schnell O, Hänel M, Krex D, Glas M. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. *J Clin Oncol* 2016; 34:1611–9.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)